DRIVIN G ROWTH - Dr. Reddy's

2.Benefits derived as a result of the
above R&D
• The company could start Commercial
production of the products viz.
Candesartan, Cilexetil,
Sumatriptan,Topiramate, Raloxifene HCL,
Repaglinide, Moxifloxacin HCl,
Stavudine, Omeprazole Magnesium,
Gatifloxacin Sesquihydrate, Rabeprazole,
Zafirlukast, Fexofenadine HCl, Zaleplon,
Montelukast Sodium
• Modification of existing manufacturing
processes for some of the products have
led to significant savings in cost of
production
• Analytical methods for new products
have been developed
• Modifications of existing manufacturing
processes for reducing the time cycle
• Patents filed with Indian Patent Office
and US Patent Office
• Developing and marketing products for
regulated markets
• Development of patentable technologies
• Regulatory submissions in time to initiate
the process of product approval
• Huge export earnings and profits.
• Able to penetrate the US generic market
intime and capture good share of the
US Generic market
• Developed and introduced new products
in therapeutic areas of Pain Management
(Fiona, Hyalosyn), Cardiovascular (Plagril,
Carvedix, Cantar), Anti-Cancer ( Tabi,
Lomtin), Nutraceuticals (Ebiza-L), Anti-
Diabetic (Diavista), Anti-infectives
(Gaity), Respiratory (Zuvair, Emlucast),
Gastrointestinal (Razo, Esomez, Trospa),
Erectile Dysfunction (Rezum)
• Developed and introduced products viz.
Nialip 250, Ciprolet XLS, Lactiflora, Nise
Spas Range, McRofy 50, Anaida Gel,
Clamp Range, Finax, Enam 20, Flustan
Range, Cytogem, Docetere 120, Semi
Reclimet, Bio E 100 & 200, Atocor 5
• Analytical methods Developed for the
following Therapeutic Segments Dental
care Products, Nutraceuticals, Women’s
Healthcare, Cardiovascular, Anti-
Diabetics, Pain Management, Anti-
Cancer, Gastrointestinal, Anti infectives,
Respiratory
3.Future plan of action
• Commercialisation of products for which
the products are under trials at Pilot Plant
level. Several new products have been
identified after a thorough study of the
market and the processes to manufacture
these products will be developed in the
R&D lab
• Intensive efforts to be made in R&D to
DR. REDDY’S LABORATORIES LTD. | DIRECTORS’ REPORT | ANNUAL REPORT 2001-2002
43